Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | FURIN | P09958 | 3/20 | 0.43 |
| ▸ | NPY4R | P50391 | 5/20 | 0.41 |
| ▸ | NPY1R | P25929 | 3/20 | 0.41 |
| ▸ | NPY2R | P49146 | 3/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 2/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7106396 | 0.99 | SSTR3 (0.52) | SSTR3KISS1RBACE1NPC1TP53 | |
| SCHEMBL521932 | 0.99 | SSTR3 (0.52) | SSTR3KISS1RBACE1NPC1TP53 | |
| SCHEMBL27319796 | 0.99 | SSTR3 (0.52) | SSTR3KISS1RBACE1NPC1TP53 | |
| SCHEMBL7888177 | 0.92 | PDF (0.45) | SSTR3NPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL1269633 | 0.90 | SSTR3 (0.51) | SSTR3KISS1RSMN1; SMN2FURINNPY4R | |
| 4-Nitroaniline SCHEMBL27576311 | 0.89 | BACE1 (0.47) | SSTR3KISS1RBACE1NPC1TP53 | |
| SCHEMBL8128688 | 0.89 | SSTR3 (0.49) | SSTR3KISS1RFURINNPY4RNPY1R | |
| SCHEMBL1088124 | 0.88 | SSTR3 (0.54) | SSTR3 | |
| Hydrochloric Acid SCHEMBL10768387 | 0.87 | NPC1 (0.50) | SSTR3NPC1TP53RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2044745 | 0.87 | NPC1 (0.50) | SSTR3NPC1TP53RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4160025-A | Method of producing a blood-coagulation-promoting preparation from human blood plasma | IMMUNO AKTIENGESELLSCHAFT FUR CHEMISCH-MEDIZINISCHE PRODUKTE (AT) | 1979-07-03 | — | — | US | claimed |
| US-9913850-B2 | Bile acids and biguanides as protease inhibitors for preserving the integrity of peptides in the gut | AXCESS LIMITED (GB) | 2018-03-13 | — | — | US | disclosed |
| EP-2873420-A1 | Bile acids and biguanides as protease inhibitors for preserving the integrity of peptides in the gut | Axcess Limited (GB) | 2015-05-20 | — | — | EP | disclosed |
| CN-103387614-B | Sea anemone Kunitz-type protease inhibitor and application thereof | UNIV PLA 2ND MILITARY MEDICAL | 2015-04-15 | — | — | CN | disclosed |
| EP-2361091-B1 | BILE ACIDS AND BIGUANIDES AS PROTEASE INHIBITORS FOR PRESERVING THE INTEGRITY OF PEPTIDES IN THE GUT | AXCESS LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| CN-103387614-A | Sea anemone Kunitz-type protease inhibitor and application thereof | UNIV PLA 2ND MILITARY MEDICAL | 2013-11-13 | — | — | CN | disclosed |
| US-20120035116-A1 | BILE ACIDS AND BIGUANIDES AS PROTEASE INHIBITORS FOR PRESERVING THE INTEGRITY OF PEPTIDES IN THE GUT | AXCESS LIMITED (GB) | 2012-02-09 | — | — | US | disclosed |
| EP-2361091-A1 | BILE ACIDS AND BIGUANIDES AS PROTEASE INHIBITORS FOR PRESERVING THE INTEGRITY OF PEPTIDES IN THE GUT | Axcess Limited (GB) | 2011-08-31 | — | — | EP | disclosed |
| US-7897364-B2 | Method for determining inhibitors of neurotrypsin | UNIVERSITY OF ZURICH (CH) | 2011-03-01 | — | — | US | disclosed |
| WO-2010037173-A1 | BILE ACIDS AND BIGUANIDES AS PROTEASE INHIBITORS FOR PRESERVING THE INTEGRITY OF PEPTIDES IN THE GUT | AXCESS LIMITED (GB) | 2010-04-08 | — | — | WO | disclosed |
| US-20090170950-A1 | Inhibitors Of Neurotrypsin | ZURICH, UNIVERSITY OF (CH) | 2009-07-02 | — | — | US | disclosed |
| US-4849353-A | DETECTION, QUANTITATIVE ANALYSIS | CORNELL RESEARCH FOUNDATION, INC. (US) | 1989-07-18 | — | — | US | disclosed |
| EP-0048989-B1 | PROCESS FOR DETERMINING INHIBITOR-ENZYME COMPLEXES | CORNELL RESEARCH FOUNDATION, INC. (US) | 1985-09-04 | — | — | EP | disclosed |
| EP-0048989-A2 | Process for determining inhibitor-enzyme complexes | CORNELL RESEARCH FOUNDATION, INC. (US) | 1982-04-07 | — | — | EP | disclosed |
| US-4308201-A | SUBSTRATES; MEDICAL DIAGNOSIS | TORII & CO., LTD. (JP) | 1981-12-29 | — | — | US | disclosed |
| US-4160025-A | Method of producing a blood-coagulation-promoting preparation from human blood plasma | IMMUNO AKTIENGESELLSCHAFT FUR CHEMISCH-MEDIZINISCHE PRODUKTE (AT) | 1979-07-03 | — | — | US | disclosed |
| US-4118481-A | LYSINE, ARGININE, TYROSINE, PROTEASE INHIBITION | BAYER AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035116-A1 | BILE ACIDS AND BIGUANIDES AS PROTEASE INHIBITORS FOR PRESERVING THE INTEGRITY OF PEPTIDES IN THE GUT | VIP, SI, SLC10A2 | SIGMAR1 4693/4885SSTR3 843/4885KISS1R 2622/4885 |
| US-20090170950-A1 | Inhibitors Of Neurotrypsin | PRSS12, BACE1, BACE2 | SIGMAR1 2312/4885SSTR3 896/4885KISS1R 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.